Journal
DIABETES OBESITY & METABOLISM
Volume 19, Issue 7, Pages 1040-1044Publisher
WILEY
DOI: 10.1111/dom.12900
Keywords
cardiovascular disease; exercise; liraglutide
Categories
Funding
- Novo Nordisk
- Novo Nordisk Fonden [NNF15OC0016230, NNF16OC0020224, NNF12OC1015904] Funding Source: researchfish
Ask authors/readers for more resources
In patients with type 2 diabetes, both supervised exercise and treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) liraglutide may improve cardiac function. We evaluated cardiac function before and after 16 weeks of treatment with the GLP-1RA liraglutide or placebo, combined with supervised exercise, in 33 dysregulated patients with type 2 diabetes on diet and/or metformin. Early diastolic myocardial tissue velocity was improved by exercise in the placebo group (mean +/- standard deviation [s.d.] -7.1 +/- 1.6 to -7.7 +/- 1.8 cm/s, P =.01), but not in the liraglutide group (-7.1 +/- 1.4 to -7.0 +/- 1.4 cm/s, P =.60; between groups, P =.02). Similarly, the mean +/- s.d. ratio of early and atrial mitral annular tissue velocities improved in the placebo group (1.0 +/- 0.4 to 1.2 +/- 0.4, P =.003), but not in the liraglutide group (1.0 +/- 0.3 to 1.0 +/- 0.3, P =.87; between groups, P =.03). We found no significant differences in heart rate, left ventricular (LV) structure or function within or between the groups. In conclusion, the addition of liraglutide to exercise in sedentary patients with dysregulated type 2 diabetes may blunt the suggested beneficial effect of exercise on LV diastolic function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available